M351-0056 is an orally active VISTA agonist with a K d value of 12.60 μM. M351-0056 inhibits the activation of the JAK2 - STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2 , and regulates type I interferon ( IFN-I ) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines ( IFN-γ , IL-17A , TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod ( HY-B0180 )-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Disease Areas > Psoriasis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JAK | Products > Signaling Pathways > STAT | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > VISTA
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.